Navigation Links
Janssen Receives Complete Response Letter From U.S. FDA For Sirukumab Biologics License Application
Date:9/23/2017

HORSHAM, Pa., Sept. 22, 2017 /PRNewswire/ -- Janssen Biotech, Inc. (Janssen) announced today that it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) seeking approval of sirukumab for the treatment of moderately to severely active rheumatoid arthritis (RA). The complete response letter indicates additional clinical data are needed to further evaluate the safety of sirukumab in the treatment of moderately to severely active RA.

"We are disappointed by this development as we feel the data accumulated to date support the efficacy and safety of sirukumab in the treatment of moderately to severely active rheumatoid arthritis," said Newman Yeilding, M.D., Head of Immunology Development, Janssen Research & Development, LLC. "We believe sirukumab represents an important therapeutic option for patients living with rheumatoid arthritis, especially for those individuals who cycle through multiple treatments and continue to struggle to find an effective option for a potentially disabling disease. We are reviewing the details of the complete response letter and plan to have a follow-up discussion with the agency to gain a full understanding of FDA requirements for U.S. approval."

On August 2, 2017, the FDA's Arthritis Advisory Committee did not recommend approval of sirukumab for RA. Convened upon the request of the FDA, the committee reviews and evaluates safety and efficacy data of human products for use in the treatment of arthritis. The committee provides non-binding recommendations based on its evaluation; however, the FDA makes the final decision on approval of the drug.

The sirukumab BLA, filed on September 23, 2016, included data from a global Phase 3 clinical development program inclusive of five studies and approximately 3,100 RA patients, including those who continued to have active disease despite previous use of disease-modifying anti-rheumatic drugs (DMARDs) and biologic treatments.

About Sirukumab
Sirukumab is a fully human monoclonal IgG1 kappa antibody that selectively blocks circulating interleukin (IL)-6, a naturally occurring protein that is believed to play a role in autoimmune conditions like RA. It is not yet approved as a treatment for rheumatoid arthritis or for any other indication anywhere in the world. Sirukumab targets the IL-6 cytokine in the treatment of RA.

Sirukumab is currently under review by health authorities in Europe and Japan as a subcutaneous therapy for the treatment of adult patients with moderately to severely active RA.

Janssen holds exclusive rights to commercialize sirukumab in Europe, the Middle East, Africa and Asia Pacific, and will regain exclusive, worldwide commercial rights in November 2017 from GSK.

About Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic, systemic inflammatory condition that is characterized by pain, joint swelling, stiffness, joint damage/tissue destruction and disability.1 Approximately 1.5 million people in the U.S. are affected by the condition for which there is no cure.2

About the Janssen Pharmaceutical Companies
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us on Twitter at https://twitter.com/JanssenGlobal.

Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Biotech, Inc., Janssen Research & Development, LLC and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; the uncertainty of commercial success; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including under "Item 1A. Risk Factors," it's most recently filed Quarterly Report on Form 10-Q, including in the section captioned "Cautionary Note Regarding Forward-Looking Statements," and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

References
1 Centers for Disease Control and Prevention. "Rheumatoid Arthritis." Available at: http://www.cdc.gov/arthritis/basics/rheumatoid.htm. Accessed June 30, 2017.
2 Arthritis Foundation. "What is Rheumatoid Arthritis?" Available at: http://www.arthritis.org/about-arthritis/types/rheumatoid-arthritis/what-is-rheumatoid-arthritis.php. Accessed June 30, 2017.

Media Contact:Investor Contacts: Brian Kenney

Joseph J. WolkOffice: 215-628-7010

Johnson & JohnsonMobile: 215-620-0111

Office: 732-524-1142Kim Rotondo

Lesley FishmanOffice: 215-628-7166

Johnson & JohnsonMobile: 267-994-1169

Office: 732-524-3922

 

View original content with multimedia:http://www.prnewswire.com/news-releases/janssen-receives-complete-response-letter-from-us-fda-for-sirukumab-biologics-license-application-300524496.html


'/>"/>
SOURCE Janssen Biotech, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Janssen Announces Two-drug Combination of Dolutegravir and Rilpivirine Demonstrates Efficacy in Maintaining Viral Suppression in Phase III Clinical Studies
2. Renova Therapeutics enters into agreement to receive stresscopin investigational new drug file from Janssen
3. Ionis Pharmaceuticals Earns Milestone Payment from Janssen for Advancing a New Program Under GI Collaboration
4. Janssen Submits Application To FDA Seeking Approval Of Anti-Interleukin-23 Monoclonal Antibody Guselkumab For The Treatment Of Moderate To Severe Plaque Psoriasis
5. British Artificial Intelligence Firm Announces Exclusive License Agreement with Janssen for Clinical Stage Drug Candidates, Facilitated by Johnson & Johnson Innovation
6. Janssen Disease Interception Unit Advances A Growing Venture Portfolio Focused On Intercepting Diseases Prior To Onset
7. Janssen Therapeutics Announces Funding for Organizations Focused on Improving Care and Treatment for Vulnerable Populations Living with HIV
8. Janssen and Johnson & Johnson to Provide Webcast Presentation on the Janssen Oncology Hematologic Malignancy Portfolio
9. WuXi AppTec Congratulates Chia Tai Tianqing Pharmaceutical Group and Janssen for Licensing Agreement
10. ViiV Healthcare to Progress Collaboration with Janssen to Develop the First Long-acting, Two Drug Injectable Regimen for Treatment of HIV-1 Infection
11. Janssen Announces Collaboration with Bavarian Nordic to Develop Vaccine for Chronic Human Papillomavirus (HPV) Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... in Las Piedras, Puerto Rico , ... Following a ... sustained minor structural damage, temporary loss of power and ... been completed, manufacturing operations have resumed, and the company ...
(Date:10/4/2017)... Oct. 4, 2017  South Korean-based healthcare product Development ... aide "cprCUBE" on Kickstarter. The device will educate the ... arrests with better efficiency compared to the dated and ... feedback on efficacy of the compression for a more ... a goal to raise $5,000. ...
(Date:10/2/2017)... Fla. , Oct. 2, 2017  AllianceRx Walgreens ... company formed by Walgreens and pharmacy benefit manager Prime ... its new brand, which included the unveiling of new ... , as well as at a few other ... the new brand to patients, some of whom will ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... locations throughout Arkansas that offers insurance and financial preparation services, is providing an ... Rock City Rescue organization. , Rock City Rescue is a locally recognized nonprofit ...
(Date:10/13/2017)... IL (PRWEB) , ... October 13, 2017 , ... ... which established the certification process to promote standards of excellence for the field ... Symposium, scheduled for March 22 – 25, 2018 in Orlando, Florida at the ...
(Date:10/13/2017)... ... ... Apple Rehab Shelton Lakes , which specializes in the delivery of ... part of a disaster drill on October 3rd. , Apple Rehab participated with the ... as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). The ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
Breaking Medicine News(10 mins):